This is an editorial discussion of published research. It is not a treatment plan.
GLP-1 agonists are everywhere right now. Semaglutide and tirzepatide strip weight fast. But the scale doesn't tell you what kind of weight you're losing. A lot of it is muscle. And the fat that's hardest to shift, the deep visceral fat wrapped around your organs, often hangs on. That's where tesamorelin enters the conversation. It's a growth hormone-releasing hormone (GHRH) analogue studied specifically for visceral adipose tissue. If you're chasing muscle definition while keeping metabolic health in check, you need to know how it stacks up against other peptides in the space.
Why Tesamorelin Gets Attention in Body Recomposition
Tesamorelin isn't new. It's FDA-approved for HIV-associated lipodystrophy, a condition where patients accumulate visceral fat and lose subcutaneous fat. The drug's ability to selectively reduce visceral adipose tissue (VAT) is what makes it interesting for physique-focused researchers. Unlike GLP-1s, which drive a calorie deficit, tesamorelin works through the GH/IGF-1 axis. It stimulates pituitary somatotrophs to release growth hormone. More GH means more lipolysis, especially in visceral depots. And because it's a GHRH analogue, it preserves the pulsatile pattern of GH release. That matters for downstream effects on muscle protein synthesis and recovery.
But here's the catch: tesamorelin's effects on muscle definition are indirect. It doesn't directly build contractile tissue. It reveals what's already there by shrinking the fat layer over it. For someone already lean, that can be a game-changer. For someone using a GLP-1 and watching their strength tank, it might help preserve lean mass, though that's not its primary studied endpoint.
Tesamorelin's Mechanism and Clinical Data
Tesamorelin is a synthetic 44-amino acid peptide identical to the first 44 residues of endogenous GHRH, with a hexenoyl group added to the N-terminus to extend half-life. It binds to GHRH receptors on the pituitary, triggering GH secretion. Because it doesn't suppress endogenous somatostatin tone, the GH pulses remain physiological. That's different from synthetic GH injections, which cause a supraphysiological spike and can downregulate natural production.
The pivotal Phase III trials showed a 15-18% reduction in VAT over 26 weeks in HIV patients, measured by CT scan. That's roughly 30 cm² of visceral fat gone. Subcutaneous fat didn't change much. Waist circumference dropped. Triglycerides improved. Lean body mass increased slightly, about 1.5 kg on average. But that lean mass gain was mostly water and organ growth, not contractile tissue. Still, for someone cutting, even a small lean mass bump while losing visceral fat is a win.
Side effects worth noting: joint pain, injection site reactions, and a bump in IGF-1 levels that can push some people above the normal range. Long-term safety beyond 26 weeks isn't well mapped. And like any GH secretagogue, it can raise blood glucose slightly, something to watch if you're already insulin resistant.
How CJC-1295 Compares
CJC-1295 is a GHRH analogue too, but with a different modification. It has a DAC (drug affinity complex) that binds to albumin, giving it a week-long half-life. That means constant GH bleed, not pulsatile release. Some researchers prefer that for convenience; others worry about receptor desensitization and prolactin spikes. In the functional fitness crowd, CJC-1295 is often paired with a GHRP like ipamorelin or GHRP-6 to amplify the GH pulse. But head-to-head, tesamorelin has better data for visceral fat reduction. CJC-1295's effects on VAT are less studied, though it does boost IGF-1 and can improve body composition over time.
For muscle preservation during a cut, CJC-1295 has some indirect support. A recent article on CJC-1295 and muscle preservation during weight loss dug into the literature. The takeaway: it might help hold onto lean mass when calories are low, but the evidence is thinner than for tesamorelin's VAT effects. And if you're worried about bone density while pushing heavy lifts, there's emerging data on CJC-1295 and bone density during muscle-building phases that's worth a look.
Where GHRP-6, Hexarelin, and BPC-157 Fit
GHRP-6 is a ghrelin mimetic. It stimulates GH release by a different pathway, the ghrelin receptor. It's often stacked with CJC-1295 to create a bigger GH pulse. But GHRP-6 also increases hunger, which can be a problem during a cut. Some researchers use it strategically around workouts to drive nutrient partitioning. Hexarelin is a stronger GHRP with a higher GH spike, but it can elevate prolactin and cortisol. Not ideal for someone already stressed from training.
BPC-157 is a different beast entirely. It's a gastric peptide studied for healing gut lining, tendons, and ligaments. It doesn't directly affect GH or fat loss. But in the trenches of a hard cut, when joints ache and digestion goes sideways, BPC-157 can keep you training. Posters in the BPC-157 thread on r/Peptides noted a similar pattern, though no formal study has tested it (PubMed). MK-677 (ibutamoren) is an oral ghrelin mimetic. It boosts GH and IGF-1 but also spikes hunger and can cause water retention. For visceral fat reduction, it's not the top pick.
Head-to-Head Evidence: Tesamorelin vs. CJC-1295
Direct comparison studies are scarce. Most data comes from separate trials. Tesamorelin's Phase III data is robust for VAT reduction. CJC-1295's body composition data is mostly from small studies and anecdotal reports. One 2006 study on CJC-1295 in healthy adults showed a 1.5-fold increase in GH secretion and a 2-fold increase in IGF-1 over 28 days, but fat mass didn't change significantly. Another 12-month study in obese adults found a 2.5 kg fat loss, but visceral fat wasn't measured separately.
For muscle definition, the edge goes to tesamorelin because of its selectivity. CJC-1295 might be better for overall recovery and sleep quality, which indirectly supports muscle retention. But if you're looking at CT scan data, tesamorelin wins. A deeper dive into the differences is in this article on tesamorelin vs. CJC-1295 for lean muscle gain.
Practical Context in a GLP-1 World
GLP-1s cause rapid weight loss. Up to 40% of that can be lean mass. That's a problem for anyone who cares about strength and metabolism. Tesamorelin won't stop muscle loss directly, but by reducing visceral